This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Potentially Unfair Tender Offer For Inhibitex Triggers Shareholder-Claim Investigation By Securities Class Action Lawyers At Goldfarb Branham LLP





DALLAS, Jan. 11, 2012 /PRNewswire/ -- Securities lawyers at Goldfarb Branham LLP are investigating whether certain officers and directors of Inhibitex, Inc. (NASDAQ: INHX) violated shareholder protection laws by agreeing to a tender offer sale of the company for $26.00 in cash per share to Bristol-Myers Squibb. Concerned Inhibitex investors are encouraged to contact class action attorney Hamilton Lindley at 877-583-2855 or hlindley@goldfarbbranham.com about their rights and remedies.

"An analyst has targeted the Inhibitex stock price at $34," said Hamilton Lindley. "While Bristol Myers may be losing patent protection on three of its four top drugs Inhibitex has powerful drugs for Hepatitits Cā€”a $20 billion market. Our proposed shareholder lawsuit seeks to ensure that the Inhibitex stockholders receive the most money and information that the law allows."  

Goldfarb Branham LLP lawyers have significant experience representing shareholders and whistleblowers in securities lawsuits nationwide. Inhibitex investors ā€“ or anyone with knowledge about this situation ā€“ should contact lawyer Hamilton Lindley at hlindley@goldfarbbranham.com or 877-583-2855.

 

Hamilton LindleyGoldfarb Branham LLP2501 N. Harwood, Ste. 1801 Dallas, TX 75201(877) 583-2855 Toll Free Telephone (214) 583-2233 Local Phone Number (214) 583-2234 Fax Number hlindley@goldfarbbranham.com www.goldfarbbranham.com

 

 

 

 

SOURCE Goldfarb Branham LLP

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs